NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $2.93 -0.07 (-2.33%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.98 +0.04 (+1.54%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Onconetix Stock (NASDAQ:ONCO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Onconetix alerts:Sign Up Key Stats Today's Range$2.93▼$3.0150-Day Range$2.67▼$4.9152-Week Range$2.61▼$552.50Volume19,886 shsAverage Volume119,550 shsMarket Capitalization$4.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Onconetix. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted34.27% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 24.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted34.27% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 24.55%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.32 News SentimentOnconetix has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Onconetix this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Onconetix to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Onconetix is held by insiders.Percentage Held by InstitutionsOnly 23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCO Stock News HeadlinesOnconetix (NASDAQ:ONCO) Shares Down 2.3% - Should You Sell?August 30 at 4:01 AM | americanbankingnews.comOnconetix Director Resignation Amid Financial AdjustmentsAugust 12, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)July 17, 2025 | globenewswire.comOnconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | finanznachrichten.deOnconetix Shares Touch All-Time Low on Reverse Merger With OcuvexJuly 16, 2025 | marketwatch.comONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to ShareholdersJuly 16, 2025 | businesswire.comOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | globenewswire.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $53.55 on January 1st, 2025. Since then, ONCO stock has decreased by 94.5% and is now trading at $2.93. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) posted its earnings results on Thursday, August, 14th. The company reported ($4.05) EPS for the quarter. The company earned $0.11 million during the quarter. Onconetix had a negative trailing twelve-month return on equity of 192.74% and a negative net margin of 3,327.03%. When did Onconetix's stock split? Onconetix's stock reverse split on Friday, June 13th 2025.The 1-85 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings8/14/2025Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.69 million Net Margins-3,327.03% Pretax Margin-3,400.45% Return on Equity-192.74% Return on Assets-89.55% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.06 Sales & Book Value Annual Sales$2.52 million Price / Sales1.80 Cash FlowN/A Price / Cash FlowN/A Book Value$11.22 per share Price / Book0.26Miscellaneous Outstanding Shares1,550,000Free Float1,498,000Market Cap$4.54 million OptionableN/A Beta3.36 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ONCO) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.